8-K
filed December 30, 2022, 6:59 PM ET
ticker CPHI
CIK 0001106644
other material
confidence high
sentiment neutral
materiality 0.55
China Pharma shareholders approve reverse stock split up to 1:10 and increase authorized shares to 500M
CHINA PHARMA HOLDINGS, INC.
- Reverse stock split at ratio up to 1:10 approved with 30,927,745 votes for, 325,290 against.
- Authorized common shares increased from 95M to 500M; approved with 30,084,494 votes for, 1,171,098 against.
- Independent directors Gene Michael Bennett, Yingwen Zhang, Baowen Dong elected to serve until next annual meeting.
- Amended and Restated 2010 Long-Term Incentive Plan adopted; 27,482,540 votes for, 824,658 against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CHINA PHARMA HOLDINGS, INC. shareholders approved Election of three independent director nominees at the 2022-12-27 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2022-12-27
Exact text from the filing
1. A proposal to elect three independent director nominees to our Board of Directors: Independent Director’s Name Votes For Votes Withheld Gene Michael Bennett 27,736,831 607,570 Yingwen Zhang 27,713,978 630,423 Baowen Dong 27,712,397 632,004 Pursuant to the foregoing votes, Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected to serve as our independent directors until the next annual meeting and until their successors are elected and qualified.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CHINA PHARMA HOLDINGS, INC. shareholders approved Amendment to Articles of Incorporation to increase authorized shares from 95,000,000 to 500,000,000 at the 2022-12-27 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2022-12-27
Exact text from the filing
4. A proposal to amend the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 95,000,000 shares to 500,000,000 shares, par value US$0.001 per share: Votes For Votes Against Abstentions 30,084,494 1,171,098 19,484 Pursuant to the foregoing votes, an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 95,000,000 shares to 500,000,000 shares, par value US$0.001 per share was approved and adopted.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CHINA PHARMA HOLDINGS, INC. shareholders approved Adoption of Amended and Restated 2010 Long-Term Incentive Plan at the 2022-12-27 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2022-12-27
Exact text from the filing
2. A proposal to adopt the Company’s Amended and Restated 2010 Long-Term Incentive Plan: Votes For Votes Against Abstentions 27,482,540 824,658 37,203 Pursuant to the foregoing votes, the Company’s Amended and Restated 2010 Long-Term Incentive Plan was approved and adopted.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CHINA PHARMA HOLDINGS, INC. shareholders approved Amendment to Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10 at the 2022-12-27 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2022-12-27
Exact text from the filing
3. A proposal to amend the Company’s Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10, such that such that every holder of common stock, par value $0.001 per share, of the Company, shall receive one share of Common Stock for up to every ten shares of Common Stock held: Votes For Votes Against Abstentions 30,927,745 325,290 22,041 Pursuant to the foregoing votes, an amendment to the Company’s Articles of Incorporation to effect a reverse stock split at a ratio of up to 1:10, such that such that every holder of common stock, par value $0.001 per share, of the Company, shall receive one share of Common Stock for up to every ten shares of Common Stock held was approved and adopted.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.